Lantheus Holdings(US:LNTH)2026-02-26 14:02Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $406.8 million, an increase of 4% year-over-year, while full-year revenue was $1.546 billion, up 0.5% [20] - Adjusted EPS for Q4 was $1.67, an increase of 4.7%, while full-year adjusted EPS was $6.08, a decrease of 10% from the prior year [26][30] - Operating cash flow for Q4 totaled $90.2 million, down from $157.7 million in Q4 2024 [27] Business Line Data and Key Metrics Changes - Radiopharmaceutical oncology, primarily from PYLARIFY, generated Q4 revenue of $240.2 million, down 9.7% year-over-year, and full-year revenue of $989.1 million, down 6.5% [20] - Precision Diagnostics delivered Q4 revenue of $143.2 million, a 22% increase, driven by DEFINITY and Neuraceq, which contributed $31 million in Q4 [21][14] - Strategic partnerships and other revenue increased by 203.3% to $23.3 million, largely due to MK-6240 [22] Market Data and Key Metrics Changes - PYLARIFY's volume grew approximately 4% year-over-year, with pricing discipline contributing to performance despite competitive pressures [12] - Neuraceq is expected to grow triple digits in 2026, driven by increased demand for Alzheimer's imaging [14] - DEFINITY maintained over 80% market share, delivering over $85 million in Q4 [14] Company Strategy and Development Direction - The company is focusing on radiodiagnostics, with plans to maintain leadership in PSMA PET imaging and prepare for the launch of a new PSMA PET formulation in Q4 2026 [8][36] - The strategic intent includes optimizing the cost structure and prioritizing investments in innovative PET radiodiagnostics [10] - The company plans to pursue value-maximizing alternatives for its radiotherapeutic assets while focusing on diagnostic opportunities [11][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive meaningful performance gains and deliver sustainable revenue growth in the mid and long term [11][36] - The company anticipates several product approvals in 2026, with a focus on commercial execution and regulatory milestones [30] - Management highlighted the importance of maintaining operational excellence and customer relationships to support growth [13] Other Important Information - The company completed the divestiture of its legacy SPECT business on January 1, 2026, to focus on PET radiodiagnostics [8] - The effective tax rate for Q4 was 19%, with a full-year rate of 25.3% [25] - Cash and cash equivalents stood at $359.1 million, with $200 million remaining for share buybacks [28] Q&A Session Summary Question: What is the timing for the new PSMA PET imaging agent's coding and reimbursement? - Management anticipates securing HCPCS code and transitional pass-through status by October 1, 2026, with a regional rollout planned for Q4 2026 [41][42] Question: How does the POSLUMA versus PYLARIFY study impact market dynamics? - Management expressed concerns about the study design and stated that its results do not factor into the current forecast for PYLARIFY [46][48] Question: Can you elaborate on pricing and unit growth for PYLARIFY in Q4? - Management indicated that Q4 performance exceeded expectations, with both volume growth and favorable pricing contributing to results [52] Question: What are the plans for radiotherapeutic assets? - Management is reviewing therapeutic assets for value optimization and may consider tuck-in acquisitions for diagnostic opportunities [61][62] Question: What is the growth outlook for Neuraceq? - Management expects Neuraceq to achieve triple-digit growth in 2026, supported by expanded manufacturing and deeper penetration in existing accounts [14][66]